Recombinant Yellow Fever Viruses Elicit CD8+ T Cell Responses and Protective Immunity against Trypanosoma cruzi

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Nogueira, Raquel Tayar ^a   Nogueira, Alanderson Rocha ^a   Pereira, Mirian Claudia Souza ^a   Rodrigues, Maurício Martins ^c   Neves, Patrícia Cristina da Costa ^a,b   Galler, Ricardo ^b   Bonaldo, Myrna Cristina ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b Instituto de Technologia em Imunobiologicos   (Brazil)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AMASTIGOTE SURFACE PROTEIN 2; COMPLEMENTARY DNA; ENVELOPE PROTEIN; EPITOPE; GAMMA INTERFERON; MICROORGANISM PROTEIN; NEUTRALIZING ANTIBODY; NONSTRUCTURAL PROTEIN 1; TRYPANOSOMA CRUZI VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

AMASTIGOTE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHAGAS DISEASE; CONTROLLED STUDY; DNA SEQUENCE; ENVELOPE GENE; FEMALE; GENETIC STABILITY; IMMUNOGENICITY; IMMUNOSTIMULATION; MOUSE; NONHUMAN; NONSTRUCTURAL PROTEIN 1 GENE; NUCLEOTIDE SEQUENCE; TRANSGENIC ORGANISM; VERO CELL; VIRUS DETECTION; VIRUS RECOMBINANT; VIRUS REPLICATION; YELLOW FEVER FLAVIVIRUS;

ANIMALS; ANTIBODIES, NEUTRALIZING; CD8-POSITIVE T-LYMPHOCYTES; CERCOPITHECUS AETHIOPS; CHAGAS DISEASE; FLUORESCENT ANTIBODY TECHNIQUE; INTERFERON-GAMMA; MICE; NEURAMINIDASE; STATISTICS, NONPARAMETRIC; TRYPANOSOMA CRUZI; VACCINES, DNA; VERO CELLS; YELLOW FEVER VIRUS;

EID: 84875122482     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059347     Document Type: Article

References (82)

1. Rassi A, Marcondes de Rezende J, (2012) American trypanosomiasis (Chagas disease). Infect Dis Clin North Am 26: 275-291.
2. Schmunis GA, Yadon ZE, (2010) Chagas disease: a Latin American health problem becoming a world health problem. Acta Trop 115: 14-21.
3. Albajar-Vinas P, Jannin J (2011) The hidden Chagas disease burden in Europe. Euro Surveill 16.
4. Quijano-Hernandez I, Dumonteil E, (2011) Advances and challenges towards a vaccine against Chagas disease. Hum Vaccin 7: 1184-1191.
5. Gulland A, (2012) Plan to stimulate research in developing countries is put on hold. BMJ 344: e3771.
6. Rodrigues M, de Alencar B, Claser C, Tzelepis F, Silveira E, et al. (2009) Swimming against the current: genetic vaccination against Trypanosoma cruzi infection in mice. Mem Inst Oswaldo Cruz 104Suppl 1: 281-287.
7. Dumonteil E, (2009) Vaccine development against Trypanosoma cruzi and Leishmania species in the post-genomic era. Infect Genet Evol 9: 1075-1082.
8. Cazorla SI, Frank FM, Malchiodi EL, (2009) Vaccination approaches against Trypanosoma cruzi infection. Expert Rev Vaccines 8: 921-935.
9. Junqueira C, Caetano B, Bartholomeu DC, Melo MB, Ropert C, et al. (2010) The endless race between Trypanosoma cruzi and host immunity: lessons for and beyond Chagas disease. Expert Rev Mol Med 12: e29.
10. Lee BY, Bacon KM, Connor DL, Willig AM, Bailey RR, (2010) The potential economic value of a Trypanosoma cruzi (Chagas disease) vaccine in Latin America. PLoS Negl Trop Dis 4: e916.
11. Martin D, Tarleton R, (2004) Generation, specificity, and function of CD8+ T cells in Trypanosoma cruzi infection. Immunol Rev 201: 304-317.
12. Rodrigues M, Boscardin S, Vasconcelos J, Hiyane M, Salay G, et al. (2003) Importance of CD8 T cell-mediated immune response during intracellular parasitic infections and its implications for the development of effective vaccines. An Acad Bras Cienc 75: 443-468.
13. Martin DL, Tarleton RL, (2005) Antigen-specific T cells maintain an effector memory phenotype during persistent Trypanosoma cruzi infection. J Immunol 174: 1594-1601.
14. Hoft D, Eickhoff C, (2005) Type 1 immunity provides both optimal mucosal and systemic protection against a mucosally invasive, intracellular pathogen. Infect Immun 73: 4934-4940.
15. Dominguez MR, Silveira EL, de VasconcelosJR, de Alencar BC, Machado AV, et al. (2011) Subdominant/cryptic CD8 T cell epitopes contribute to resistance against experimental infection with a human protozoan parasite. PLoS One 6: e22011.
16. Laucella S, Postan M, Martin D, Hubby Fralish B, Albareda M, et al. (2004) Frequency of interferon- gamma-producing T cells specific for Trypanosoma cruzi inversely correlates with disease severity in chronic human Chagas disease. J Infect Dis 189: 909-918.
17. Aliberti JC, Souto JT, Marino AP, Lannes-Vieira J, Teixeira MM, et al. (2001) Modulation of chemokine production and inflammatory responses in interferon-gamma- and tumor necrosis factor-R1-deficient mice during Trypanosoma cruzi infection. Am J Pathol 158: 1433-1440.
18. Silva JS, Vespa GN, Cardoso MA, Aliberti JC, Cunha FQ, (1995) Tumor necrosis factor alpha mediates resistance to Trypanosoma cruzi infection in mice by inducing nitric oxide production in infected gamma interferon-activated macrophages. Infect Immun 63: 4862-4867.
19. de Alencar B, Persechini P, Haolla F, de Oliveira G, Silverio J, et al. (2009) Perforin and gamma interferon expression are required for CD4+ and CD8+ T-cell-dependent protective immunity against a human parasite, Trypanosoma cruzi, elicited by heterologous plasmid DNA prime-recombinant adenovirus 5 boost vaccination. Infect Immun 77: 4383-4395.
20. Gutierrez FR, Mineo TW, Pavanelli WR, Guedes PM, Silva JS, (2009) The effects of nitric oxide on the immune system during Trypanosoma cruzi infection. Mem Inst Oswaldo Cruz 104Suppl 1: 236-245.
21. Tzelepis F, de Alencar B, Penido M, Gazzinelli R, Persechini P, et al. (2006) Distinct kinetics of effector CD8+ cytotoxic T cells after infection with Trypanosoma cruzi in naive or vaccinated mice. Infect Immun 74: 2477-2481.
22. Pérez Brandan C, Basombrío MA (2012) Genetically attenuated Trypanosoma cruzi parasites as a potential vaccination tool. Bioengineered 3.
23. Cazorla S, Frank F, Becker P, Arnaiz M, Mirkin G, et al. (2010) Redirection of the immune response to the functional catalytic domain of the cystein proteinase cruzipain improves protective immunity against Trypanosoma cruzi infection. J Infect Dis 202: 136-144.
24. Eickhoff CS, Giddings OK, Yoshida N, Hoft DF, (2010) Immune responses to gp82 provide protection against mucosal Trypanosoma cruzi infection. Mem Inst Oswaldo Cruz 105: 687-691.
25. Araújo A, de Alencar B, Vasconcelos J, Hiyane M, Marinho C, et al. (2005) CD8+-T-cell-dependent control of Trypanosoma cruzi infection in a highly susceptible mouse strain after immunization with recombinant proteins based on amastigote surface protein 2. Infect Immun 73: 6017-6025.
26. Hoft DF, Eickhoff CS, Giddings OK, Vasconcelos JR, Rodrigues MM, (2007) Trans-sialidase recombinant protein mixed with CpG motif-containing oligodeoxynucleotide induces protective mucosal and systemic trypanosoma cruzi immunity involving CD8+ CTL and B cell-mediated cross-priming. J Immunol 179: 6889-6900.
27. Duan X, Yonemitsu Y, Chou B, Yoshida K, Tanaka S, et al. (2009) Efficient protective immunity against Trypanosoma cruzi infection after nasal vaccination with recombinant Sendai virus vector expressing amastigote surface protein-2. Vaccine 27: 6154-6159.
28. Machado AV, Cardoso JE, Claser C, Rodrigues MM, Gazzinelli RT, et al. (2006) Long-term protective immunity induced against Trypanosoma cruzi infection after vaccination with recombinant adenoviruses encoding amastigote surface protein-2 and trans-sialidase. Hum Gene Ther 17: 898-908.
29. Miyahira Y, Takashima Y, Kobayashi S, Matsumoto Y, Takeuchi T, et al. (2005) Immune responses against a single CD8+-T-cell epitope induced by virus vector vaccination can successfully control Trypanosoma cruzi infection. Infect Immun 73: 7356-7365.
30. Takayama E, Ono T, Carnero E, Umemoto S, Yamaguchi Y, et al. (2010) Quantitative and qualitative features of heterologous virus-vector-induced antigen-specific CD8+ T cells against Trypanosoma cruzi infection. Int J Parasitol 40: 1549-1561.
31. Rigato PO, de Alencar BC, de VasconcelosJR, Dominguez MR, Araújo AF, et al. (2011) Heterologous plasmid DNA prime-recombinant human adenovirus 5 boost vaccination generates a stable pool of protective long-lived CD8(+) T effector memory cells specific for a human parasite, Trypanosoma cruzi. Infect Immun 79: 2120-2130.
32. Limon-Flores AY, Cervera-Cetina R, Tzec-Arjona JL, Ek-Macias L, Sánchez-Burgos G, et al. (2010) Effect of a combination DNA vaccine for the prevention and therapy of Trypanosoma cruzi infection in mice: role of CD4+ and CD8+ T cells. Vaccine 28: 7414-7419.
33. Sanchez-Burgos G, Mezquita-Vega RG, Escobedo-Ortegon J, Ramirez-Sierra MJ, Arjona-Torres A, et al. (2007) Comparative evaluation of therapeutic DNA vaccines against Trypanosoma cruzi in mice. FEMS Immunol Med Microbiol 50: 333-341.
34. Cazorla S, Frank F, Becker P, Corral R, Guzmán C, et al. (2008) Prime-boost immunization with cruzipain co-administered with MALP-2 triggers a protective immune response able to decrease parasite burden and tissue injury in an experimental Trypanosoma cruzi infection model. Vaccine 26: 1999-2009.
35. Morell M, Thomas MC, Caballero T, Alonso C, López MC, (2006) The genetic immunization with paraflagellar rod protein-2 fused to the HSP70 confers protection against late Trypanosoma cruzi infection. Vaccine 24: 7046-7055.
36. Egui A, Thomas MC, Morell M, Marañón C, Carrilero B, et al. (2012) Trypanosoma cruzi paraflagellar rod proteins 2 and 3 contain immunodominant CD8(+) T-cell epitopes that are recognized by cytotoxic T cells from Chagas disease patients. Mol Immunol 52: 289-298.
37. Taibi A, Plumas-Marty B, Guevara-Espinoza A, Schöneck R, Pessoa H, et al. (1993) Trypanosoma cruzi: immunity-induced in mice and rats by trypomastigote excretory-secretory antigens and identification of a peptide sequence containing a T cell epitope with protective activity. J Immunol 151: 2676-2689.
38. Planelles L, Thomas MC, Alonso C, López MC, (2001) DNA immunization with Trypanosoma cruzi HSP70 fused to the KMP11 protein elicits a cytotoxic and humoral immune response against the antigen and leads to protection. Infect Immun 69: 6558-6563.
39. Vasconcelos J, Hiyane M, Marinho C, Claser C, Machado A, et al. (2004) Protective immunity against trypanosoma cruzi infection in a highly susceptible mouse strain after vaccination with genes encoding the amastigote surface protein-2 and trans-sialidase. Hum Gene Ther 15: 878-886.
40. Garg N, Tarleton R, (2002) Genetic immunization elicits antigen-specific protective immune responses and decreases disease severity in Trypanosoma cruzi infection. Infect Immun 70: 5547-5555.
41. de Alencar B, Araújo A, Penido M, Gazzinelli R, Rodrigues M, (2007) Cross-priming of long lived protective CD8+ T cells against Trypanosoma cruzi infection: importance of a TLR9 agonist and CD4+ T cells. Vaccine 25: 6018-6027.
42. Dutra WO, Menezes CA, Villani FN, da Costa GC, da Silveira AB, et al. (2009) Cellular and genetic mechanisms involved in the generation of protective and pathogenic immune responses in human Chagas disease. Mem Inst Oswaldo Cruz 104Suppl 1: 208-218.
43. Silveira E, Claser C, Haolla F, Zanella L, Rodrigues M, (2008) Novel protective antigens expressed by Trypanosoma cruzi amastigotes provide immunity to mice highly susceptible to Chagas' disease. Clin Vaccine Immunol 15: 1292-1300.
44. Martin D, Weatherly D, Laucella S, Cabinian M, Crim M, et al. (2006) CD8+ T-Cell responses to Trypanosoma cruzi are highly focused on strain-variant trans-sialidase epitopes. PLoS Pathog 2: e77.
45. Theiler M, Smith HH (2000) The use of yellow fever virus modified by in vitro cultivation for human immunization. J. Exp. Med. 65, 787-800 (1937). Rev Med Virol 10: 6-16; discussion 13-15.
46. Poland J, Calisher C, Monath T, Downs W, Murphy K, (1981) Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine. Bull World Health Organ 59: 895-900.
47. Lefeuvre A, Marianneau P, Deubel V, (2004) Current Assessment of Yellow Fever and Yellow Fever Vaccine. Curr Infect Dis Rep 6: 96-104.
48. Querec T, Bennouna S, Alkan S, Laouar Y, Gorden K, et al. (2006) Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J Exp Med 203: 413-424.
49. Stoyanov C, Boscardin S, Deroubaix S, Barba-Spaeth G, Franco D, et al. (2010) Immunogenicity and protective efficacy of a recombinant yellow fever vaccine against the murine malarial parasite Plasmodium yoelii. Vaccine 28: 4644-4652.
50. Franco D, Li W, Qing F, Stoyanov C, Moran T, et al. (2010) Evaluation of yellow fever virus 17D strain as a new vector for HIV-1 vaccine development. Vaccine 28: 5676-5685.
51. Co M, Terajima M, Cruz J, Ennis F, Rothman A, (2002) Human cytotoxic T lymphocyte responses to live attenuated 17D yellow fever vaccine: identification of HLA-B35-restricted CTL epitopes on nonstructural proteins NS1, NS2b, NS3, and the structural protein E. Virology. 293: 151-163.
52. van der Most RG, Harrington LE, Giuggio V, Mahar PL, Ahmed R, (2002) Yellow fever virus 17D envelope and NS3 proteins are major targets of the antiviral T cell response in mice. Virology 296: 117-124.
53. Miller J, van der Most R, Akondy R, Glidewell J, Albott S, et al. (2008) Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity 28: 710-722.
54. Monath T, Barrett A, (2003) Pathogenesis and pathophysiology of yellow fever. Adv Virus Res 60: 343-395.
55. Neves PC, Rudersdorf RA, Galler R, Bonaldo MC, de Santana MG, et al. (2010) CD8+ gamma-delta TCR+ and CD4+ T cells produce IFN-γ at 5-7 days after yellow fever vaccination in Indian rhesus macaques, before the induction of classical antigen-specific T cell responses. Vaccine 28: 8183-8188.
56. Tzelepis F, Persechini P, Rodrigues M, (2007) Modulation of CD4(+) T cell-dependent specific cytotoxic CD8(+) T cells differentiation and proliferation by the timing of increase in the pathogen load. PLoS One 2: e393.
57. Nogueira RT, Nogueira AR, Pereira MC, Rodrigues MM, Galler R, et al. (2011) Biological and immunological characterization of recombinant Yellow Fever 17D viruses expressing a Trypanosoma cruzi Amastigote Surface Protein-2 CD8+ T cell epitope at two distinct regions of the genome. Virol J 8: 127.
58. Bonaldo M, Mello S, Trindade G, Rangel A, Duarte A, et al. (2007) Construction and characterization of recombinant flaviviruses bearing insertions between E and NS1 genes. Virol J 4: 115.
59. Bonaldo M, Martins M, Rudersdorf R, Mudd P, Sacha J, et al. (2010) Recombinant yellow fever vaccine virus 17D expressing simian immunodeficiency virus SIVmac239 gag induces SIV-specific CD8+ T-cell responses in rhesus macaques. J Virol 84: 3699-3706.
60. Boscardin S, Kinoshita S, Fujimura A, Rodrigues M, (2003) Immunization with cDNA expressed by amastigotes of Trypanosoma cruzi elicits protective immune response against experimental infection. Infect Immun 71: 2744-2757.
61. Bonaldo M, Garratt R, Caufour P, Freire M, Rodrigues M, et al. (2002) Surface expression of an immunodominant malaria protein B cell epitope by yellow fever virus. J Mol Biol 315: 873-885.
62. Rice C, Grakoui A, Galler R, Chambers T, (1989) Transcription of infectious yellow fever RNA from full-length cDNA templates produced by in vitro ligation. New Biol 1: 285-296.
63. Brener Z, (1969) The behavior of slender and stout forms of Trypanosoma cruzi in the blood-stream of normal and immune mice. Ann Trop Med Parasitol 63: 215-220.
64. Lima-Junior JC, Tran TM, Meyer EV, Singh B, De-Simone SG, et al. (2008) Naturally acquired humoral and cellular immune responses to Plasmodium vivax merozoite surface protein 9 in Northwestern Amazon individuals. Vaccine 26: 6645-6654.
65. Liniger M, Zuniga A, Naim HY, (2007) Use of viral vectors for the development of vaccines. Expert Rev Vaccines 6: 255-266.
66. Low HP, Tarleton RL, (1997) Molecular cloning of the gene encoding the 83 kDa amastigote surface protein and its identification as a member of the Trypanosoma cruzi sialidase superfamily. Molecular and biochemical parasitology 88: 137-149.
67. Low HP, Santos MA, Wizel B, Tarleton RL, (1998) Amastigote surface proteins of Trypanosoma cruzi are targets for CD8+ CTL. Journal of immunology 160: 1817-1823.
68. Wizel B, Palmieri M, Mendoza C, Arana B, Sidney J, et al. (1998) Human infection with Trypanosoma cruzi induces parasite antigen-specific cytotoxic T lymphocyte responses. The Journal of clinical investigation 102: 1062-1071.
69. Rodrigues MM, Boscardin SB, Vasconcelos JR, Hiyane MI, Salay G, et al. (2003) Importance of CD8 T cell-mediated immune response during intracellular parasitic infections and its implications for the development of effective vaccines. Anais da Academia Brasileira de Ciencias 75: 443-468.
70. Mudd P, Piaskowski S, Neves P, Rudersdorf R, Kolar H, et al. (2010) The live-attenuated yellow fever vaccine 17D induces broad and potent T cell responses against several viral proteins in Indian rhesus macaques-implications for recombinant vaccine design. Immunogenetics 62: 593-600.
71. Reyes-Sandoval A, Rollier CS, Milicic A, Bauza K, Cottingham MG, et al. (2012) Mixed Vector Immunization With Recombinant Adenovirus and MVA Can Improve Vaccine Efficacy While Decreasing Antivector Immunity. Mol Ther.
72. Miyahira Y, (2008) Trypanosoma cruzi infection from the view of CD8+ T cell immunity-an infection model for developing T cell vaccine. Parasitol Int 57: 38-48.
73. Todd DJ, Lee AH, Glimcher LH, (2008) The endoplasmic reticulum stress response in immunity and autoimmunity. Nat Rev Immunol 8: 663-674.
74. Green DR, Ferguson T, Zitvogel L, Kroemer G, (2009) Immunogenic and tolerogenic cell death. Nat Rev Immunol 9: 353-363.
75. Heath W, Carbone F, (2001) Cross-presentation in viral immunity and self-tolerance. Nat Rev Immunol 1: 126-134.
76. Amigorena S, Savina A, (2010) Intracellular mechanisms of antigen cross presentation in dendritic cells. Curr Opin Immunol 22: 109-117.
77. Bachmann MF, Jennings GT, (2010) Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol 10: 787-796.
78. Akondy R, Monson N, Miller J, Edupuganti S, Teuwen D, et al. (2009) The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response. J Immunol 183: 7919-7930.
79. Goonetilleke N, Moore S, Dally L, Winstone N, Cebere I, et al. (2006) Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes. J Virol 80: 4717-4728.
80. Seder RA, Darrah PA, Roederer M, (2008) T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 8: 247-258.
81. Trindade GF, de Santana MG, dos Santos JR, Galler R, Bonaldo MC, (2012) Retention of a recombinant GFP protein expressed by the yellow fever 17D virus in the E/NS1 intergenic region in the endoplasmic reticulum. Mem Inst Oswaldo Cruz 107: 262-272.
82. Claser C, Espíndola N, Sasso G, Vaz A, Boscardin S, et al. (2007) Immunologically relevant strain polymorphism in the Amastigote Surface Protein 2 of Trypanosoma cruzi. Microbes Infect 9: 1011-1019.